SAN DIEGO, June 30, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
technologies designed to provide physicians with clinically
actionable information to improve the outcomes of patients with
cancer, announces that it has been awarded Canadian Patent 2812291,
entitled METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION. This
patent covers methods for enhancing the detection of cells using
fluorescent complexes, including circulating tumor cells (CTCs),
and from a biological fluid. The issuance of this patent
increases Biocept's total patent awards for use in its molecular
diagnostics business to 40.
The method covered by this patent expands Biocept's patent
protection for sensitive detection of cancer cells. It
combines seamlessly with Biocept's core technologies using
antibodies for CTC enrichment, as well as Biocept's microchannel
intellectual property for the capture, enrichment, and imaging of
CTCs from patients with cancer.
"Expanding patent protection for our Target Selector™ liquid
biopsy platform is among our strategic priorities as we seek to
grow our global business," said Michael
Nall, Biocept's President and CEO. "This patent
expands Biocept's international footprint for capturing and
analyzing rare cells of interest, including CTCs, and is a further
aid for detecting cancer cells recovered from biological fluids
such as blood or cerebrospinal fluid. With this newly granted
patent, we now have 40 issued patents covering our molecular
diagnostic technologies, and expect to further strengthen our
intellectual property position with additional patent issuances in
the future."
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. Additionally,
Biocept is offering nationwide COVID-19 polymerase chain reaction
(PCR) testing to support public health efforts during this
unprecedented pandemic. For more information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements as to our expectation of further strengthening our
intellectual property position with additional patent issuances in
the future and the ability of our tests to provide clinically
actionable information to oncologist and their patients, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-awarded-canadian-patent-covering-the-enhanced-detection-of-rare-cells-including-cancer-cells-from-a-biological-fluid-sample-such-as-blood-or-cerebrospinal-fluid-301085669.html
SOURCE Biocept, Inc.